Cargando…

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile

Background: The target product profile (TPP) outlines the desired profile of a target product aimed at a particular disease and is used by companies to plan clinical development. Considering the increasing importance of health technology assessment (HTA) in informing reimbursement decisions, a robus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ting, McAuslane, Neil, Goettsch, Wim G., Leufkens, Hubert G. M., De Bruin, Marie L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340272/ https://www.ncbi.nlm.nih.gov/pubmed/35924050 http://dx.doi.org/10.3389/fphar.2022.948161

Ejemplares similares

Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study
por: Wang, Ting, et al.
Publicado: (2020)

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
por: Liberti, Lawrence, et al.
Publicado: (2017)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

The Reliability and Relevance of a Quality of Decision Making Instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for Use During the Lifecycle of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2019)

Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature
por: Bujar, Magdalena, et al.
Publicado: (2017)

Quality Decision-Making Practices in Pharmaceutical Companies and Regulatory Authorities: Current and Proposed Approaches to Its Documentation
por: Bujar, Magdalena, et al.
Publicado: (2020)

Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice
por: Rodier, Céline, et al.
Publicado: (2020)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

P31 Impact of COVID-19 on HTA/PRMA of Medicinal Products in Europe: A Payer Perspective
por: Mycka, J, et al.
Publicado: (2022)

Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
por: Hogervorst, Milou A, et al.
Publicado: (2023)

Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
por: Schelleman, Hedi, et al.
Publicado: (2015)

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions
por: Bujar, Magdalena, et al.
Publicado: (2021)

Patient and Payer Preferences for Additional Value Criteria
por: Jakab, Ivett, et al.
Publicado: (2021)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

HTA51 Challenges and Opportunities of Health Technology Assessment in Older Adult Immunization
por: van Dorst, P, et al.
Publicado: (2022)

A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2020)

Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International Experience
por: Gałązka-Sobotka, Małgorzata, et al.
Publicado: (2021)

Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
por: Ermisch, Michael, et al.
Publicado: (2016)

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation
por: Vella Bonanno, Patricia, et al.
Publicado: (2017)

An evaluation of the Caribbean regulatory system centralized assessment process for medicines submitted 2017–2018 using the OpERA methodology
por: Liberti, Lawrence, et al.
Publicado: (2020)

To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016
por: Kühler, Thomas Christian, et al.
Publicado: (2019)

PNS173 Impact of COVID-19 on HTA Bodies and Pharmaceutical Company Pricing and Market Access Activities
por: Thomas, M., et al.
Publicado: (2020)

Pharmaceutical companies’ views on a health technology assessment (HTA) entity in Saudi Arabia
por: Al-Omar, Hussain Abdulrahman, et al.
Publicado: (2020)

Evaluation of the effectiveness and efficiency of the East African community joint assessment procedure by pharmaceutical companies: Opportunities for improvement
por: Ngum, Nancy, et al.
Publicado: (2022)

Drug Shortages From the Perspectives of Authorities and Pharmacy Practice in the Netherlands: An Observational Study
por: Postma, Doerine J., et al.
Publicado: (2018)

Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe
por: ten Ham, Renske M.T., et al.
Publicado: (2018)

Nutrition, a health technology that deserves increasing interest among HTA doers. A systematic review
por: Gutiérrez-Ibarluzea, Iñaki, et al.
Publicado: (2015)

Getting the Right Evidence After Drug Approval
por: Vreman, Rick A., et al.
Publicado: (2020)

An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?
por: Kanavos, Panos, et al.
Publicado: (2019)

Pharmacogenetics – Challenges and Opportunities Ahead
por: Zanger, Ulrich M.
Publicado: (2010)

Value Insider Season 1 Episode 1: The Importance of Payers and HTA: How Did We End Up Here? (Introduction to Value) [Podcast]
por: Drummond, Michael F, et al.
Publicado: (2022)

Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities
por: Porta, Exequiel O. J., et al.
Publicado: (2023)

Implementation of a Framework for an Abridged Review Using Good Reliance Practices: Optimising the Medicine Regulatory Review Process in South Africa
por: Keyter, Andrea, et al.
Publicado: (2020)

Payer Perspectives on Health Technology Assessment
por: Watkins, John B.
Publicado: (2012)

Biosimilars: Opportunities to Promote Optimization Through Payer and Provider Collaboration
por: Manolis, Chronis H., et al.
Publicado: (2016)

Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada
por: Tony, Michèle, et al.
Publicado: (2011)

Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities
por: McAuslane, Neil, et al.
Publicado: (2023)

Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation
por: Limdi, Nita A.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_r44v5psb2vmbvtlm9g5d59rgh1